18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size (Q45288484)

11 December 2017

title

18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size (English)

1 reference

Fluorodeoxyglucose Positron Emission Tomography

11 December 2017

0 references

1 reference

6

Ferdinando Squitieri

1 reference

11 December 2017

Andrea Ciarmiello

1

1 reference

11 December 2017

Giampiero Giovacchini

2

1 reference

11 December 2017

Sara Orobello

3

1 reference

11 December 2017

Laura Bruselli

4

1 reference

11 December 2017

Francesca Elifani

5

1 reference

11 December 2017

publication date

12 April 2012

1 reference

11 December 2017

number of pages

7

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

11 December 2017

volume

39

1 reference

11 December 2017

issue

6

1 reference

11 December 2017

page(s)

1030-1036

1 reference

Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease.

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease

21 January 2018

2 references

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

21 January 2018

12 December 2020

Metabolic correlates of levodopa response in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Family and molecular data for a fine analysis of age at onset in Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Seeking brain biomarkers for preventive therapy in Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Informed consent: study of quality of information given to participants in a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Unsupervised, automated segmentation of the normal brain using a multispectral relaxometric magnetic resonance approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Striatal size, glucose metabolic rate, and verbal learning in normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

The meaning and use of the area under a receiver operating characteristic (ROC) curve

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Onset and rate of striatal atrophy in preclinical Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Selective defect of in vivo glycolysis in early Huntington's disease striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Early defect of transforming growth factor β1 formation in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

DNA instability in postmitotic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

DNA instability in replicating Huntington's disease lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Unified Huntington's disease rating scale: Reliability and consistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-012-2114-Z

Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis

21 January 2018

1 reference

12 December 2020

Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.

1 reference

12 December 2020

The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size

1 reference

12 December 2020

Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.

1 reference

12 December 2020

Correction for partial volume effects in PET: principle and validation

1 reference

12 December 2020

Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction

1 reference

12 December 2020

Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats

1 reference

12 December 2020

10.1007/S00259-012-2114-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

1034271569

0 references

1 reference